The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some current weight loss solutions, retatrutide appears to offer a significant substantial loss in body size and improve metabolic markers, partic